MRNA Relative Valuation
MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRNA is overvalued; if below, it's undervalued.
Historical Valuation
Moderna Inc (MRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -40.36. The fair price of Moderna Inc (MRNA) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 31.97 USD , Moderna Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：31.97
Fair
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.23
P/B
Median3y
2.57
Median5y
6.86
-32.45
FCF Yield
Median3y
-8.40
Median5y
-1.35
Competitors Valuation Multiple
The average P/S ratio for MRNA's competitors is 8.95, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -35.33%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Moderna Inc (MRNA) currently overvalued or undervalued?
What is Moderna Inc (MRNA) fair value?
How does MRNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Moderna Inc (MRNA) as of Jul 18 2025?
What is the current FCF Yield for Moderna Inc (MRNA) as of Jul 18 2025?
What is the current Forward P/E ratio for Moderna Inc (MRNA) as of Jul 18 2025?